Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (560) clinical trials

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

In this study the investigators want to find out whether the use of a low dose of levetiracetam (LEV) in healthy adults with the Apolipoprotein e4 gene (APOE 4) can reduce abnormal hippocampal network activity. The investigators also want to study whether this low dose of LEV can improve memory ...

Phase

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's Disease on a stable dose of 10 mg donepezil with or without memantine standard of care.

Phase

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

To evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. ...

Phase

Effect of CT1812 Treatment on Brain Synaptic Density

This is a single-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for up 180 days.

Phase

An Open-Label Crenezumab Study in Patients With Alzheimer's Disease

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg IV Q4W will be offered to all patients who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in patients on long-term crenezumab treatment and to investigate the effect of crenezumab on ...

Phase

Sleep Aging and Risk for Alzheimer's 2.0

Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may increase amyloid burden and represent risk factors for cognitive decline in the elderly. We will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and amyloid deposition using C-PiB PET/MR both at baseline and at the ...

Phase N/A

BABEL Advance Care Planning in Long-term Care

2.0 SPECIFIC AIMS 2.1. Aim 1. Improve intervention acceptability, buy-in, and usability by engaging a diverse group of stakeholders to collaboratively design key details of the study. Aim 1A: The stakeholder group work to identify and agree upon key principles and practical aspects of ACP in the NH setting. Aim ...

Phase N/A

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

New research suggests that exposure to a light flickering at 40Hz may promote gamma brain wave activity through the photic entrainment phenomenon. These waves have the potential to activate critical cleaning cells in the brain that could eliminate beta amyloid plaques. The most recent research on light therapy for Alzheimer's ...

Phase N/A

The Chinese Familial Alzheimer's Network

Set up a multi-center, national-wide FAD research network and electronic database platform in China, including ADAD cohort of the known mutations PSEN1, PSEN2 and APP (mutation carriers and noncarriers; presymptomatic and symptomatic) and unknown mutation cohort. Clarify the genetic characteristic of familial Alzheimer's disease, and find risk and protective genes ...

Phase N/A

Evaluation of a New CBT for People With Alzheimer's Disease and Their Caregivers

A large percentage of people with dementia (including Alzheimer's disease) suffer from psychological distress characterized by severe symptoms of anxiety, depression or insomnia. This psychological distress can disrupt their daily functioning and deteriorate their quality of life. The presence of anxiety, depression or insomnia can also accelerate cognitive decline in ...

Phase N/A